South America Point of Care Diagnostics Market Outlook, 2031

Market Drivers

• High epidemiological burden of endemic infectious and chronic diseases: South America faces a complex, dual health burden characterized by high rates of endemic tropical and infectious diseases alongside rapidly rising chronic illness prevalence. Vector-borne and infectious pathogens such as Dengue fever, Zika virus, Chikungunya, Chagas disease, Malaria, HIV, and Tuberculosis frequently surge across tropical zones, requiring immediate, on-site clinical screening to prevent community outbreaks. Concurrently, changing dietary habits and aging demographics across major economies like Brazil, Argentina, and Colombia have caused a surge in chronic conditions, notably type 2 diabetes, hypertension, and cardiovascular diseases.
• Public healthcare expansion and infrastructure modernization in remote regions: Geographic barriers pose a fundamental challenge to healthcare equity across South America, where vast populations reside in geographically isolated areas such as the Amazon Basin, the Andean highlands, and rural agricultural provinces. Building and maintaining centralized, fully equipped reference laboratories in these remote locations is economically and logistically unfeasible due to poor transport infrastructure and unreliable sample cold chains. To bridge these disparities, national health initiatives such as Brazil’s Unified Health System (SUS) and regional public health campaigns supported by the Pan American Health Organization (PAHO) are actively procuring and deploying decentralized diagnostic solutions.

Market Challenges

• Economic volatility, currency fluctuations, and severe pricing pressures: Macroeconomic instability, high inflation rates, and severe currency devaluations present significant operational hurdles for medtech companies operating in South America. Because the vast majority of advanced point-of-care platforms such as microfluidic chips, automated molecular analyzers, and high-precision electronic meters are manufactured in North America, Europe, or Asia, they are imported in foreign currencies (primarily USD or EUR). When local currencies weaken, the procurement cost of imported diagnostic hardware and disposable reagent cartridges rises sharply.
• Regulatory fragmentation, approval delays, and infrastructure deficits: Navigating the regulatory landscape in South America requires clearing disparate national regulatory processes across individual member states. Foreign medtech companies must secure separate product approvals from distinct regulatory bodies such as ANVISA in Brazil, ANMAT in Argentina, and INVIMA in Colombia each maintaining its own technical documentation requirements, quality system inspections, and local clinical trial mandates. Obtaining regulatory clearances from agencies like ANVISA can take months or years, delaying commercial launches.

Market Trends

• Proliferation of smartphone-integrated readers and mobile health (mHealth) platforms: High mobile connectivity rates across South America are driving rapid convergence between point-of-care diagnostics and mHealth technology. Emerging diagnostic platforms utilize smartphone cameras, Bluetooth connectivity, and dedicated software apps to turn consumer smartphones into diagnostic readers. Field health workers and patients can capture high-resolution images of rapid lateral-flow strips or electrochemical sensors, allowing AI algorithms or cloud-based software to objectively interpret test results and eliminate manual visual reading errors.
• Growth of over-the-counter (OTC) self-testing and retail pharmacy networks: Driven by shifting consumer preferences post-pandemic and legislative updates favoring expanded pharmacy services, patient self-testing and retail diagnostic access are growing rapidly across urban South America. Countries like Brazil have expanded the scope of practice for retail community pharmacies, allowing pharmacists to administer point-of-care rapid tests for blood glucose, cholesterol, Dengue, Beta-hCG, and respiratory viral infections. Simultaneously, there is rising consumer demand for prescription-free, over-the-counter (OTC) home diagnostic kits for ongoing chronic disease monitoring.